Eurofins CDMO Alphora Inc. (Canada) Announces Completion of New API Manufacturing Facility

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Eurofins CDMO Alphora Inc. is excited to announce an expansion of its API capacity and capabilities with the completion of its new API manufacturing facility at its site in Mississauga, Canada. The new API facility adds 15,000 sq ft of GMP processing and warehousing space which complements Eurofins CDMO Alphora’s existing API and drug substance manufacturing capabilities.

The addition of 2 x 2000 L reactors expands existing GMP plant capacity and supports API batches to the 125kg scale. The new plant provides additional capacity for Phase I through to commercialization programs to support a growing client base and pipeline. The facility is designed to handle up to Safebridge Class 3 compounds and includes two Hastelloy filter dryers to facilitate API isolation and drying. The reactor systems can support temperatures from cryogenic (-80⁰C) to 200⁰C, as well as hydrogenations and biotage chromatography.

The API plant expansion positions Eurofins CDMO Alphora at the forefront of small molecule development and supporting the manufacturing of life-saving therapies. This capacity expansion will allow Eurofins CDMO Alphora to support existing and prospective partners to address expanding therapeutic indications and meet the growing demand for emerging therapies at clinical and commercial stages. With its 20-year history in developing and manufacturing highly complex processes for a variety of APIs and HPAPIs, as well as its integrated offerings in Solid-State R&D and Oral Drug Product Formulation, Eurofins CDMO Alphora is a well-stablished CDMO partner of choice.

To learn more, visit: https://www.eurofins.com/cdmo

About Eurofins CDMO Alphora Inc.
Eurofins CDMO, part of the international network of Eurofins laboratories, is a leading global Contract Development and Manufacturing Organization that provides clients with active pharmaceutical ingredients (“API’s”) / drug substance and drug product development for small molecules, biologics and phytocannabinoids. Its service offering encompasses drug substance/API development, solid state research and development, pre-formulation, formulation and development, analytical development, Non-GMP & GMP manufacturing, upstream development, downstream development & ADC Conjugation. Operating with facilities in Europe, North America and India, Eurofins CDMO is accredited through the FDA, EMA, ANSM, ANSES, FAMHP, PMDA, and Health Canada.

About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With ca. 62,000 staff across a network of more than 900 laboratories in over 1,000 companies in 62 countries, Eurofins offers a portfolio of over 200,000 analytical methods.

Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.